IXICO PLC · LSE:IXI

IXICO — FY2020 Earnings Presentation

20 slides from IXICO's earnings presentation, Dec 2, 2020

  1. Slide 1: FY20 Results

    Slide 1: FY20 Results

    FY20 Results 2nd December 2020 Giulio Cerroni Grant Nash Lammert Albers CEO CFO CCO

  2. Slide 2: Nonregulated Disclaimer

    Slide 2: Nonregulated Disclaimer

    Nonregulated Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which incl

  3. Slide 3: Addressing a major unmet clinical need in neurological diseases

    Slide 3: Addressing a major unmet clinical need in neurological diseases

    Addressing a major unmet clinical need in neurological diseases Costs of bringing a drug to market are high and increasing Dementia is the Total worldwide Ageing population cost of dementia [2] The number of only major cause 131.5m people in the world of death we can’t with dementia is expected to p

  4. Slide 4: A company with a meaningful purpose & strong values

    Slide 4: A company with a meaningful purpose & strong values

    A company with a Our purpose is to advance medicine and human health by turning data meaningful purpose into clinically meaningful information, providing valuable new insights in neuroscience. & strong values. 4

  5. Slide 5: What we do

    Slide 5: What we do

    What we do 5 CONFDENTIAL, BUSINESS USE ONLY © IXICO plc 2020

  6. Slide 6: AI data analytics to accelerate biopharma innovation

    Slide 6: AI data analytics to accelerate biopharma innovation

    AI data analytics to accelerate biopharma innovation Eligibility / Stratification Safety - Side effects Efficacy PET - Alzheimer’s disease MRI - Immunotherapy MRI - Huntington’s disease Accurately measure the absence/presence of Detect adverse drug reactions Accurately measure biomarkers that track

  7. Slide 7: Global fight against AD today: continuum of collaboration

    Slide 7: Global fight against AD today: continuum of collaboration

    Global fight against AD today: continuum of collaboration PCORI (Patient- MOPEAD (Models of AlzForum DIAN (Dominantly Centered Outcomes DPUK DDF (Dementia Patient Engagement (Alzheimer Inherited Alzheimer Research (Dementias Discovery for Alzheimer's Forum) Network) Institute) Platform UK) Fund) Dis

  8. Slide 8: Sustained delivery of strong financial performance

    Slide 8: Sustained delivery of strong financial performance

    Sustained delivery of strong financial performance 26% 120bps £0.8m 9.5 1.3 65 67 7.6 59 0.5 56 5.4 45 4.1 3.1 -0.6 -1.4 -2.1 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 ̶ FY20 +26% ̶ Sustained strong margins ̶ More than doubling of profitability ̶ Growth despite chall

  9. Slide 9: Investing for future growth; controlling costs

    Slide 9: Investing for future growth; controlling costs

    Investing for future growth; controlling costs £0.3m £0.4m £0.2m 2.0 60% 30% 70% 2.0 64% 3.5 52% 25% 56% 50% 25% 60% 51% 3.0 1.5 20% 1.5 31% 0.2 40% 17% 50% 40% 2.5 20% 14% 15% 40% 34% 2.0 1.0 0.2 30% 15% 1.0 19% 17% 30% 1.5 15% 20% 10% 0.5 20% 0.5 1.0 10% 5% 10% 0.5 1.6 1.3 1.0 1.0 1.3 0.8 0.8 0.8

  10. Slide 10: Building financial strength

    Slide 10: Building financial strength

    Building financial strength £0.6m £0.3m £1.2m 7.2 7.3 7.6 9.1 7.9 7.3 7.9 7.9 7.3 3.1 2.4 1.5 3.3 3.9 2.5 2.7 -0.1 -0.1 -1.2 -2.0 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 Cash (£m) Op Cashflow (£m) ̶ Growing balance sheet ̶ Profitability feeding through to ̶ Growing

  11. Slide 11: Investment plans for 2021; investing for strong growth in FY22 and beyond

    Slide 11: Investment plans for 2021; investing for strong growth in FY22 and beyond

    Investment plans for 2021; investing for strong growth in FY22 and beyond Alliance Management Next generation Growing our portfolio Process improvement image capture and of intelligent AI analysis platform algorithms • Investing to further • Investing in the • Investing in our • Investing in a cultu

  12. Slide 12: 4 Year Track Record

    Slide 12: 4 Year Track Record

    4 Year Track Record 9.5 7.6 5.4 4.1 14% 3.1 6% -12% 1.3 0.5 -34% -68% -0.6 -1.4 -2.1 2016 2017 2018 2019 2020 Revenues (£M) EBITDA (£M) EBITDA Margin % 12 BUSINESS USE ONLY © IXICO plc 2020

  13. Slide 13: Impact of Covid-19 to IXICO study portfolio

    Slide 13: Impact of Covid-19 to IXICO study portfolio

    Impact of Covid-19 to IXICO study portfolio Clinical Sites: Patients: Continuity Remote Delivery models: • Focus on local laws and • Motivated patients • Missed visits/dosing often • Imaging centres remain open regulation • Unmet medical need no reason for • Innovation • Geographic diversity in late

  14. Slide 14: FY20: Revenue & Bookings

    Slide 14: FY20: Revenue & Bookings

    FY20: Revenue & Bookings By Indication By Trial Phase FY Revenue FY Bookings FY Revenue FY Bookings 14 BUSINESS USE ONLY © IXICO plc 2020

  15. Slide 15: Order book & Sales Pipeline

    Slide 15: Order book & Sales Pipeline

    Order book & Sales Pipeline £5.8m Indication Group Trial Phase 21.7 19.3 15.9 12.7 9.9 2016 2017 2018 2019 2020 ̶ Growth trend absorbs 33% revenue CAGR across 4 years Consulting ̶ Record order book at FY20 close; 36% increase on prior year. Rare Neurological Natural History Studies Phase I ̶ Deliver

  16. Slide 16: Rare and Orphan Diseases

    Slide 16: Rare and Orphan Diseases

    Rare and Orphan Diseases 7,000 Orphan / Rare Diseases FDA Orphan Drug Approvals 70 60 50 40 34 18 21 30 11 13 17 21 Orphan 11 9 Non-Orphan 20 5 8 9 7 6 9 6 10 25 13 17 12 17 17 15 19 26 18 24 24 13 28 25 27 0 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 Global Genes, allies in rare disease 16 BUS

  17. Slide 17: Repeat Expansion Disorders (RED)

    Slide 17: Repeat Expansion Disorders (RED)

    Repeat Expansion Disorders (RED) Disease Sequence # repeats Gene > 50 known REDs Huntington’s Disease (HD) CAG > 36 HTT •Each caused by DNA repetitions in a single gene Friedreich’s ataxia (FA) GAA > 70 FXN •Mostly severe with no disease- Spinocerebellar ataxia (SCA) CAG > 52 ATXN3 modifying therapi

  18. Slide 18: Diversification in Alzheimer's disease drug targets

    Slide 18: Diversification in Alzheimer's disease drug targets

    Diversification in Alzheimer’s disease drug targets • There are 121 agents in commercial clinical trials for the treatment for AD. • IXICO active portfolio covers less than 5% of assets • 97 agents are putative disease modifying • Increased diversification in drug targets • Driving increasing demand

  19. Slide 19: Well positioned for the year ahead - Investing for growth

    Slide 19: Well positioned for the year ahead - Investing for growth

    Well positioned for the year ahead - Investing for growth Launching innovative Leveraging our Building scale in Continuously enhancing new products expertise into new high growth our client value indications markets proposition Algorithms to Unrivalled domain Established A decade of measure disease

  20. Slide 20: Questions

    Slide 20: Questions

    Questions AIM: IXI

Source: Internet Archive copy of ixico.com

More decks from IXICO PLC

All 11 IXICO decks